Brief: Lepu Biopharma Announces Inside Information On Exclusive License Deal With Astrazeneca For CMG901
23/02/2023 24:41
Feb 23 (Reuters) - Lepu Biopharma Co Ltd 2157.HK :
* INSIDE INFORMATION ANNOUNCEMENT EXCLUSIVE LICENSE
AGREEMENT WITH
ASTRAZENECA FOR CMG901
* KYM BIOSCIENCES INC ENTERED INTO A GLOBAL EXCLUSIVE
OUT-LICENSE
AGREEMENT WITH ASTRAZENECA AB
* UNDER AGREEMENT, KYM TO RECEIVE AN UPFRONT PAYMENT OF
US$63
MILLION WITH POTENTIAL FOR ADDITIONAL PAYMENTS UP TO US$1,125
MILLION
* ASTRAZENECA WILL BE GRANTED EXCLUSIVE GLOBAL LICENSE FOR
RESEARCH, DEVELOPMENT, MANUFACTURING, AND COMMERCIALIZATION,
AMONG OTHERS OF CMG901
Source text for Eikon: ID:nHKSb9F5dy
Further company coverage: 2157.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lepu Biopharma
See all newsChina's Lepu Biopharma H1 revenue rises 12.1% on higher drug sales
Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
Brief: Lepu Biopharma Reports Positive Top-Line Results From Global Phase III Trial Of CMG901 (AZD0901)
Lepu Biopharma set to jump most in 7 months on FY profit forecast
Brief: Lepu Biopharma Expects FY Net Profit Attributable